Leadership Overview
Catalent has 10 executives leading key functions including revenue generation, marketing, finance, operations, technology, and human resources.
Driven by innovation, Catalent is dedicated to optimizing product development, launch, and full life-cycle supply for patients worldwide, serving as a preferred Contract Development and Manufacturing Organization for personalized medicines and blockbuster drugs.
Driven by innovation, Catalent is dedicated to optimizing product development, launch, and full life-cycle supply for patients worldwide, serving as a preferred Contract Development and Manufacturing Organization for personalized medicines and blockbuster drugs.
Leadership Roles at Catalent
Matti Masanovich - Senior VP & Chief Financial Officer
Matti Masanovich, the Senior VP & Chief Financial Officer at Catalent, directs all financial operations and strategic fiscal planning. Masanovich oversees capital allocation, investment strategies, and financial risk management to support Catalent's global expansion and operational objectives. This critical role involves ensuring robust financial health and driving profitability across the company's diverse service offerings, from development sciences to multi-modality manufacturing. Matti Masanovich provides essential financial oversight for optimizing product development, launch, and full life-cycle supply chains. The focus is on maintaining financial integrity and enabling sustainable growth as a preferred CDMO partner.
Christopher Hajjar - Vice President, Finance & Biologics, Corporate Financial Planning & Analysis Segment Chief Financial Officer
Christopher Hajjar, the Vice President, Finance & Biologics, Corporate Financial Planning & Analysis Segment Chief Financial Officer at Catalent, manages financial planning and analysis for key segments. Hajjar oversees the financial health and strategic resource allocation for the biologics division and corporate FP&A functions. This position involves detailed financial modeling, forecasting, and performance analysis to support Catalent's growth in personalized medicines and complex drug development. Christopher Hajjar ensures financial discipline and provides critical insights to drive operational efficiency and profitability across the organization. The objective is to support Catalent's mission of optimizing product development and supply chains.
Ricky Hopson - Group President, Clinical and Specialty Services and Chief of Staff
Ricky Hopson, the Group President, Clinical and Specialty Services and Chief of Staff at Catalent, leads critical operational divisions and advises executive leadership. Hopson directs the strategic development and execution of clinical trial services and specialty manufacturing solutions, enhancing Catalent's capabilities in personalized medicine. As Chief of Staff, Ricky Hopson ensures seamless coordination across departments and drives key strategic initiatives to optimize product development and full life-cycle supply. This role involves fostering operational excellence and ensuring alignment with the company's mission to serve patients globally. The focus is on enhancing service delivery and operational efficiency.
Aris Gennadios - Group President, Pharma & Consumer Health Segment
Aris Gennadios, the Group President, Pharma & Consumer Health Segment at Catalent, directs strategic operations across critical business units. Gennadios oversees the development and execution of market strategies for pharmaceutical and consumer health products, ensuring alignment with global demand and regulatory landscapes. This leadership position involves driving innovation in drug development and manufacturing processes, supporting clients in bringing vital medicines and health products to patients worldwide. Aris Gennadios champions operational excellence and fosters cross-functional collaboration to enhance Catalent's capabilities as a preferred Contract Development and Manufacturing Organization. The focus is on optimizing product launch and full life-cycle supply chains.
Aris Gennadios - Group President, Pharma & Consumer Health
Aris Gennadios, the Group President, Pharma & Consumer Health at Catalent, spearheads strategic initiatives within the pharmaceutical and consumer health sectors. Gennadios guides the expansion of Catalent's service offerings, focusing on optimizing product development and manufacturing for a diverse client base. This role involves ensuring seamless integration of advanced delivery technologies and multi-modality manufacturing capabilities to support personalized medicines and blockbuster drugs. Aris Gennadios drives operational efficiency and market responsiveness, reinforcing Catalent's position as a leading Contract Development and Manufacturing Organization. The objective is to enhance full life-cycle supply chain solutions for global patient access.
Kassandra Walsh - Senior Account Director & Chief Revenue Officer
Kassandra Walsh, the Senior Account Director & Chief Revenue Officer at Catalent, drives revenue generation and client relationship management. Overseeing global sales strategies, Walsh ensures alignment with corporate growth objectives and market penetration targets. This leadership role involves expanding market share through strategic account development and optimizing the sales funnel. By fostering strong partnerships with pharmaceutical, biotech, and consumer health clients, Kassandra Walsh directly impacts the company's financial performance and secures long-term revenue streams. The focus remains on delivering value-added solutions that support product development and full life-cycle supply for patients.
Shouryadeep Srivastava - Chief Medical Officer, Consulting & Chief Marketing Officer
Shouryadeep Srivastava, the Chief Medical Officer, Consulting & Chief Marketing Officer at Catalent, provides critical medical expertise and drives market strategy. Srivastava oversees consulting services, offering deep scientific insights to clients developing novel therapeutics and personalized medicines. Concurrently, as Chief Marketing Officer, Srivastava shapes Catalent's brand narrative and market positioning, emphasizing its role as a preferred CDMO. This dual leadership ensures that scientific innovation is effectively communicated and aligned with market needs, supporting product development and full life-cycle supply. Shouryadeep Srivastava's focus is on translating complex scientific advancements into market opportunities.
Charles Lickfold - Senior Vice President, Chief Technology Officer
Charles Lickfold, the Senior Vice President, Chief Technology Officer at Catalent, architects and directs the company's technological infrastructure and innovation roadmap. Lickfold oversees the integration of advanced digital solutions and manufacturing technologies to enhance Catalent's capabilities in developing and producing complex pharmaceuticals and biologics. This leadership role is pivotal in driving efficiency, scalability, and quality across all operational facets, from early-stage development to full life-cycle supply. Charles Lickfold ensures that Catalent remains at the forefront of technological advancement, supporting the optimization of product development for patients worldwide. The emphasis is on leveraging technology to accelerate drug delivery and manufacturing.
Lisa Evoli - Senior Vice President and Chief Human Resources Officer
Lisa Evoli, the Senior Vice President and Chief Human Resources Officer at Catalent, leads all human capital strategies and organizational development initiatives. Evoli focuses on cultivating a high-performance culture that supports innovation and collaboration across Catalent's global workforce. This role is essential for attracting, retaining, and developing top talent in the pharmaceutical, biotech, and consumer health sectors. Lisa Evoli ensures that HR policies and programs align with Catalent's mission to optimize product development and full life-cycle supply, fostering an environment where employees can thrive. The objective is to build a skilled and engaged team dedicated to patient well-being.
Trish Hunt - Group Vice President & Chief Marketing Officer
Trish Hunt, the Group Vice President & Chief Marketing Officer at Catalent, directs global marketing strategies and brand management. Hunt oversees the development and execution of campaigns that highlight Catalent's expertise in product development, launch, and full life-cycle supply for pharma, biotech, and consumer health partners. This leadership position involves shaping market perception and driving demand for Catalent's comprehensive CDMO services, including personalized medicines and blockbuster drugs. Trish Hunt ensures consistent brand messaging and market engagement across all regions. The focus is on communicating Catalent's value proposition and reinforcing its position as a preferred partner in the life sciences industry.
Explore Leadership Teams in Manufacturing
GSK plc is a British multinational pharmaceutical and biotechnology company headquartered in London, United Kingdom. Established in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, GSK is the tenth-largest pharmaceutical company globally. The company discovers, develops, manufactures, and delivers medicines and vaccines with a research and development focus on four primary therapeutic areas: respiratory, immunology and inflammation, oncology, HIV, and infectious diseases. GSK's product portfolio includes specialty medicines, vaccines, and general medicines targeting conditions such as HIV, respiratory diseases, cancer, immuno-inflammation, anti-viral, central nervous system disorders, metabolic conditions, cardiovascular disease, urogenital conditions, anti-bacterial treatments, dermatology, and rare diseases. The company also offers over-the-counter products for pain relief, oral health, nutrition, skin health, and gastrointestinal diseases. GSK has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. In July 2024, the company moved its global headquarters to New Oxford Street in central London, positioning itself within the city's Knowledge Quarter near world-class science and academic institutions including the Francis Crick Institute and King's College London. The new headquarters houses approximately 3,000 employees including the global leadership team and teams supporting research and development, supply chain, commercial operations, and corporate functions. GSK sells its products through wholesalers, pharmacies, hospitals, physicians, and other healthcare groups globally, aiming to positively impact the health of 2.5 billion people by the end of the decade.
Company Leadership MD
CJ
GN
Johnson & Johnson is a global healthcare company that develops pharmaceuticals and medical technologies. It provides innovative medicines, surgical products, and medical devices used in areas such as oncology, immunology, neuroscience, and cardiovascular care, serving healthcare providers and patients worldwide.
Company Leadership
DB
CC
RD
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) -selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.
Company Leadership
JJ
SK
RF
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Company Leadership TI
JS
MD
Frequently Asked Questions Regarding Catalent Top Executives and Leadership Team
